JP2015522360A - 心耳用閉塞装置およびその製造方法 - Google Patents
心耳用閉塞装置およびその製造方法 Download PDFInfo
- Publication number
- JP2015522360A JP2015522360A JP2015521803A JP2015521803A JP2015522360A JP 2015522360 A JP2015522360 A JP 2015522360A JP 2015521803 A JP2015521803 A JP 2015521803A JP 2015521803 A JP2015521803 A JP 2015521803A JP 2015522360 A JP2015522360 A JP 2015522360A
- Authority
- JP
- Japan
- Prior art keywords
- distal
- strut
- struts
- proximal
- cage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001008 atrial appendage Anatomy 0.000 title claims abstract description 34
- 238000004519 manufacturing process Methods 0.000 title claims description 18
- 238000000034 method Methods 0.000 claims description 51
- 238000005520 cutting process Methods 0.000 claims description 13
- 238000005452 bending Methods 0.000 claims description 12
- 210000001316 polygonal cell Anatomy 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003292 glue Substances 0.000 claims 1
- 229910000679 solder Inorganic materials 0.000 claims 1
- 239000003814 drug Substances 0.000 description 25
- 239000012528 membrane Substances 0.000 description 24
- 239000000463 material Substances 0.000 description 22
- 229940079593 drug Drugs 0.000 description 21
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 238000003466 welding Methods 0.000 description 10
- 239000000853 adhesive Substances 0.000 description 9
- 230000001070 adhesive effect Effects 0.000 description 9
- 210000005248 left atrial appendage Anatomy 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- -1 Elgiloy and Physox Chemical class 0.000 description 8
- 208000007536 Thrombosis Diseases 0.000 description 7
- 229910045601 alloy Inorganic materials 0.000 description 7
- 239000000956 alloy Substances 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 229910001000 nickel titanium Inorganic materials 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000005476 soldering Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 210000002837 heart atrium Anatomy 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 150000002739 metals Chemical class 0.000 description 6
- 229920000728 polyester Polymers 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229920004934 Dacron® Polymers 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 229920000954 Polyglycolide Polymers 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000000560 biocompatible material Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000003698 laser cutting Methods 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000004633 polyglycolic acid Substances 0.000 description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010003658 Atrial Fibrillation Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 229920002988 biodegradable polymer Polymers 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 229920001610 polycaprolactone Polymers 0.000 description 3
- 239000004632 polycaprolactone Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920000544 Gore-Tex Polymers 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 229910001260 Pt alloy Inorganic materials 0.000 description 2
- 229910000639 Spring steel Inorganic materials 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 2
- KGXDGSMJNUPTEQ-UHFFFAOYSA-N [Ti].[Ni].[Pt] Chemical compound [Ti].[Ni].[Pt] KGXDGSMJNUPTEQ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 229920000249 biocompatible polymer Polymers 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000000788 chromium alloy Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 238000002788 crimping Methods 0.000 description 2
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 2
- 239000013013 elastic material Substances 0.000 description 2
- 229910000701 elgiloys (Co-Cr-Ni Alloy) Inorganic materials 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 210000005246 left atrium Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical class [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 239000012781 shape memory material Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229910052715 tantalum Inorganic materials 0.000 description 2
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 2
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 2
- 239000010937 tungsten Substances 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- BLTXWCKMNMYXEA-UHFFFAOYSA-N 1,1,2-trifluoro-2-(trifluoromethoxy)ethene Chemical compound FC(F)=C(F)OC(F)(F)F BLTXWCKMNMYXEA-UHFFFAOYSA-N 0.000 description 1
- BZPCMSSQHRAJCC-UHFFFAOYSA-N 1,2,3,3,4,4,5,5,5-nonafluoro-1-(1,2,3,3,4,4,5,5,5-nonafluoropent-1-enoxy)pent-1-ene Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)=C(F)OC(F)=C(F)C(F)(F)C(F)(F)C(F)(F)F BZPCMSSQHRAJCC-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- QBBTZXBTFYKMKT-UHFFFAOYSA-N 2,3-diacetyloxypropyl acetate Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O.CC(=O)OCC(OC(C)=O)COC(C)=O QBBTZXBTFYKMKT-UHFFFAOYSA-N 0.000 description 1
- LPEKGGXMPWTOCB-UHFFFAOYSA-N 8beta-(2,3-epoxy-2-methylbutyryloxy)-14-acetoxytithifolin Natural products COC(=O)C(C)O LPEKGGXMPWTOCB-UHFFFAOYSA-N 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- REIYHFWZISXFKU-UHFFFAOYSA-N Butyl acetoacetate Chemical compound CCCCOC(=O)CC(C)=O REIYHFWZISXFKU-UHFFFAOYSA-N 0.000 description 1
- MRABAEUHTLLEML-UHFFFAOYSA-N Butyl lactate Chemical compound CCCCOC(=O)C(C)O MRABAEUHTLLEML-UHFFFAOYSA-N 0.000 description 1
- IEPRKVQEAMIZSS-UHFFFAOYSA-N Di-Et ester-Fumaric acid Natural products CCOC(=O)C=CC(=O)OCC IEPRKVQEAMIZSS-UHFFFAOYSA-N 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- IEPRKVQEAMIZSS-WAYWQWQTSA-N Diethyl maleate Chemical compound CCOC(=O)\C=C/C(=O)OCC IEPRKVQEAMIZSS-WAYWQWQTSA-N 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZIJKGAXBCRWEOL-SAXBRCJISA-N Sucrose octaacetate Chemical compound CC(=O)O[C@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1 ZIJKGAXBCRWEOL-SAXBRCJISA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 239000001083 [(2R,3R,4S,5R)-1,2,4,5-tetraacetyloxy-6-oxohexan-3-yl] acetate Substances 0.000 description 1
- 239000001344 [(2S,3S,4R,5R)-4-acetyloxy-2,5-bis(acetyloxymethyl)-2-[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxolan-3-yl] acetate Substances 0.000 description 1
- UAOKXEHOENRFMP-ZJIFWQFVSA-N [(2r,3r,4s,5r)-2,3,4,5-tetraacetyloxy-6-oxohexyl] acetate Chemical compound CC(=O)OC[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)C=O UAOKXEHOENRFMP-ZJIFWQFVSA-N 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001191 butyl (2R)-2-hydroxypropanoate Substances 0.000 description 1
- VFGRALUHHHDIQI-UHFFFAOYSA-N butyl 2-hydroxyacetate Chemical compound CCCCOC(=O)CO VFGRALUHHHDIQI-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 229940072645 coumadin Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- PCYQQSKDZQTOQG-NXEZZACHSA-N dibutyl (2r,3r)-2,3-dihydroxybutanedioate Chemical compound CCCCOC(=O)[C@H](O)[C@@H](O)C(=O)OCCCC PCYQQSKDZQTOQG-NXEZZACHSA-N 0.000 description 1
- OLLQYIBTJXUEEX-UHFFFAOYSA-N diethyl 3-hydroxypentanedioate Chemical compound CCOC(=O)CC(O)CC(=O)OCC OLLQYIBTJXUEEX-UHFFFAOYSA-N 0.000 description 1
- OUWSNHWQZPEFEX-UHFFFAOYSA-N diethyl glutarate Chemical compound CCOC(=O)CCCC(=O)OCC OUWSNHWQZPEFEX-UHFFFAOYSA-N 0.000 description 1
- YSAVZVORKRDODB-WDSKDSINSA-N diethyl tartrate Chemical compound CCOC(=O)[C@@H](O)[C@H](O)C(=O)OCC YSAVZVORKRDODB-WDSKDSINSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PVRATXCXJDHJJN-UHFFFAOYSA-N dimethyl 2,3-dihydroxybutanedioate Chemical compound COC(=O)C(O)C(O)C(=O)OC PVRATXCXJDHJJN-UHFFFAOYSA-N 0.000 description 1
- XTDYIOOONNVFMA-UHFFFAOYSA-N dimethyl pentanedioate Chemical compound COC(=O)CCCC(=O)OC XTDYIOOONNVFMA-UHFFFAOYSA-N 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- ZANNOFHADGWOLI-UHFFFAOYSA-N ethyl 2-hydroxyacetate Chemical compound CCOC(=O)CO ZANNOFHADGWOLI-UHFFFAOYSA-N 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000010329 laser etching Methods 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940057867 methyl lactate Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000412 polyarylene Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 229920006132 styrene block copolymer Polymers 0.000 description 1
- 229940013883 sucrose octaacetate Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 239000003803 thymidine kinase inhibitor Substances 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229950009819 zotarolimus Drugs 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12122—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder within the heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12168—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
- A61B17/12172—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure having a pre-set deployed three-dimensional shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12168—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
- A61B17/12177—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure comprising additional materials, e.g. thrombogenic, having filaments, having fibers or being coated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00526—Methods of manufacturing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
- A61B2017/00893—Material properties pharmaceutically effective
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B2017/1205—Introduction devices
- A61B2017/12054—Details concerning the detachment of the occluding device from the introduction device
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B2017/1205—Introduction devices
- A61B2017/12054—Details concerning the detachment of the occluding device from the introduction device
- A61B2017/12095—Threaded connection
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Prostheses (AREA)
- Surgical Instruments (AREA)
Abstract
Description
支柱は略多角形断面を有していてもよい。その他の形状の断面を有する支柱を利用することも本発明の範囲に含まれる。支柱は、支柱が相互に結合する頂点を有した複数の閉鎖多角形セルを形成してもよい。支柱がその他の形状のセルを形成することも本発明の範囲に含まれる。
通常、遠位支柱端のうち少なくともいくつかは近位支柱端に接続される。
ケージ状構造はシングルカット構造で形成してもよい。
閉塞装置は近位端にネジ式インサートをさらに備えていてもよい。
1つ以上の実施形態において、本発明は、近位端と遠位端および中心軸を有し、支柱で形成されるケージ状構造を備えた閉塞装置を対象とする。支柱は近位支柱端と遠位支柱端を有する。装置の近位端において、支柱は中心軸に向かって延在し、近位支柱端で相互に接続される。装置の遠位端において、支柱のうち少なくともいくつかは中心軸と近位端に向かって延在し、遠位支柱端が装置の最遠位部分に近接して配置されるように遠位支柱端で相互に接続される。
図9は、本発明に係る閉塞装置10の製造に使用できる管状構造201を示す。該構造は、支柱によって形成されるパターンを示すため巻かれずに平坦な状態で示す。管状構造201は管状体のレーザ切断、またはエッチングおよび/または切断されたシート材料の圧延などのその他の適切なプロセスによって製造される。
適用のため、医薬品は溶剤または補助溶剤の混合物に溶解させることができ、添加剤はコーティング成分に添加させてもよい。
その他の適切なポリマ添加剤は、ポリスチレン−ポリイソブチレン−ポリスチレン三ブロックコポリマ(SIBS)などのスチレンブロックコポリマを含むブロックコポリマ、ポリエチレン酸化物などのヒドロゲル、シリコーンゴム、および/または任意のその他の適切なポリマ材料を含むがそれらに限定されない。
実施形態によると、本発明は、上述の閉塞装置のいずれかを形成するように構成されるパターンを有する管状構造にも関することができる。
さらに、本発明は心耳用閉塞装置の製造方法に関する。該方法は、(a)近位端と遠位端を有する管状体を切断して支柱を有する管状構造を設けるステップであって、支柱のうち少なくともいくつかが遠位端でばらばらの遠位支柱端を有するステップと、(b)管状構造の少なくとも一部を拡張させるステップと、(c)ばらばらの遠位支柱端が管状構造の近位端に向かう方向を向くように、ばらばらの遠位支柱端のうち少なくともいくつかを管状構造の内部に向かって曲げるステップと、(d)ばらばらの遠位支柱端のうち少なくともいくつかを相互に接続するステップと、を備える。
当業者であれば認識するように、上述のステップのいくつかのシーケンスは本発明の実施形態で変更してもよい。なお、上述の実施形態は技術的に実行可能に組み合わせてもよく、各自の特徴は併せて提供することができる。
本発明は特に以下の形態を備える。
形態3.支柱が略多角形断面を有する形態1または2による閉塞装置。
形態4.支柱が頂点を有する複数の閉鎖多角形セルを形成し、支柱が上記頂点で相互に結合する形態1、2、または3のいずれか1つによる閉塞装置。
形態6.曲げられた支柱の端部のうち少なくともいくつかがケージ状構造の近位端に向かう方向を向く形態5による閉塞装置。
形態8.遠位支柱端のうち少なくともいくつかが固定手段を設ける形態1ないし7のいずれか1つによる閉塞装置。
形態10.遠位支柱端のうち少なくともいくつかが近位支柱端に接続される形態1ないし9のいずれか1つによる閉塞装置。
形態12.近位端で支柱がケージ状構造内で相互に接続される形態1ないし10のいずれか1つによる閉塞装置。
形態14.遠位支柱端が、遠位支柱端に圧着および/または溶接されるチューブ、遠位支柱端を収容するいくつかの開口部を備えるカラー、収縮チューブ、フィラメント、溶接、半田付け、接着剤のうちの1つまたはその組み合わせによって相互に接続される形態1ないし13のいずれか1つによる閉塞装置。
形態16.ケージ状構造内で相互に接続される遠位支柱端の数が、(i)6個以上、(ii)10個以上、(iii)12個以上、(iv)18個、または
(v)26個
である形態1ないし15のいずれか1つによる閉塞装置。
形態18.フィルタをさらに備える形態1ないし17のいずれか1つによる閉塞装置。
形態20.心耳用閉塞装置の製造方法であって、a)近位端と遠位端を有する管状体を切断して支柱を有する管状構造を設けるステップであって、支柱のうち少なくともいくつかが遠位端でばらばらの遠位支柱端を有するステップと、b)管状構造の少なくとも一部を拡張させるステップと、c)ばらばらの遠位支柱端が管状構造の近位端に向かう方向を向くように、管状構造の内部に向かってばらばらの遠位支柱端のうち少なくともいくつかを曲げるステップと、d)ばらばらの遠位支柱端のうち少なくともいくつかを相互に接続するステップと、を備える方法。
形態22.切断部が管状体の近位端まで延在せずに、近位端と一体形成される近位カラーによって近位支柱端を接続する形態20による方法。
形態24.遠位支柱端が、管状構造の長の
(i)約20%〜65%、
(ii)約30%〜55%、
(iii)約40%〜50%、または
(iv)約45%
の長を占める形態19ないし22による方法。
形態26.ばらばらの遠位支柱端が、管状構造を形成する他の支柱と壁厚および/または支柱幅が異なる形態19ないし24による方法。
形態29.ばらばらの遠位支柱端のうち少なくともいくつかを相互に接続するステップが、チューブを遠位支柱端に圧着および/または溶接することを備える形態27または28による方法。
形態31.ばらばらの遠位支柱端のうち少なくともいくつかが近位端で支柱に接続される形態20ないし30のいずれか1つによる方法。
形態33.近位支柱端が上記管状構造の遠位端に向かう方向を向くように、管状構造の内部に向かって近位支柱端のうち少なくともいくつかを曲げるステップと、近位支柱端のうち少なくともいくつかを相互に接続するステップと、をさらに備える形態20、21および23ないし31のいずれか1つによる方法。
本発明を図面と上記説明において詳細に例示し説明したが、このような例示と説明は例であり、限定と考えるべきではない。当業者によって以下の請求項の範囲内で変更や修正が可能であると理解される。特に、本発明は、上述の様々な実施形態の特徴の組み合わせを備えた追加の実施形態も対象とする。
Claims (20)
- 心耳用閉塞装置であって、近位端と遠位端および中心軸を有し、支柱で形成されるケージ状構造を備え、前記支柱が近位支柱端と遠位支柱端を有し、該装置の前記近位端において、前記支柱が前記中心軸に向かって延在し、近位支柱端で相互に接続され、前記支柱のうち少なくともいくつかが前記ケージ状構造内の遠位支柱端で相互に接続されて該装置の非外傷性遠位端を形成する閉塞装置。
- 前記ケージ状構造が一体形管状体から切断される請求項1の閉塞装置。
- 前記支柱が略多角形断面を有する請求項1の閉塞装置。
- 前記支柱が頂点を有する複数の閉鎖多角形セルを形成し、前記支柱が前記頂点で相互に結合する請求項1の閉塞装置。
- 前記非外傷性遠位端が内側に曲げられた支柱を備える請求項1の閉塞装置。
- 前記曲げられた支柱の端部のうち少なくともいくつかが前記ケージ状構造の前記近位端に向かう方向を向く請求項5の閉塞装置。
- 前記支柱のうち少なくともいくつかが、遠位支柱端が前記中心軸に略平行に延在するように曲げられる請求項5の閉塞装置。
- 前記遠位支柱端のうち少なくともいくつかがアンカーを設ける請求項1の閉塞装置。
- 前記アンカーを設ける支柱のうち少なくともいくつかが前記ケージ状構造を通って延在する請求項8の閉塞装置。
- 前記遠位支柱端のうち少なくともいくつかが近位支柱端に接続される請求項1の閉塞装置。
- 前記近位支柱端が前記ケージ状構造外で相互に接続される請求項1の閉塞装置。
- 前記近位支柱端が前記ケージ状構造内で相互に接続される請求項1の閉塞装置。
- 前記近位支柱端が、支柱端に一体形成される近位カラーによって相互に接続される請求項1の閉塞装置。
- 前記遠位支柱端が、前記遠位支柱端に圧着および/または溶接されるチューブ、前記遠位支柱端を収容するいくつかの開口部を備えるカラー、溶接、半田付け、収縮チューブ、フィラメント、接着剤のうちの1つまたはその組み合わせによって相互に接続される請求項1の閉塞装置。
- 前記遠位支柱端が、前記ケージ状構造を形成するその他の支柱と壁厚および/または支柱幅が一部または全部異なる請求項1の閉塞装置。
- 前記ケージ状構造がシングルカット構造で形成される請求項1の閉塞装置。
- フィルタをさらに備える請求項1の閉塞装置。
- 前記近位端にネジ式インサートをさらに備える請求項1の閉塞装置。
- 近位端と遠位端および中心軸を有し、支柱で形成されるケージ状構造を備える閉塞装置であって、前記支柱が近位支柱端と遠位支柱端を有し、該装置の前記近位端において、前記支柱が前記中心軸に向かって延在し、近位支柱端で相互に接続され、該装置の前記遠位端において、前記支柱のうち少なくともいくつかが前記中心軸と近位端に向かって延在し、前記遠位支柱端が装置の最遠位部分に近接して配置されるように、遠位支柱端で相互に接続される閉塞装置。
- 心耳用閉塞装置の製造方法であって、
a)近位端と遠位端を有する管状体を切断して支柱を有する管状構造を設けるステップであって、前記遠位端で前記支柱のうち少なくともいくつかがばらばらの遠位支柱端を有するステップと、
b)前記管状構造の少なくとも一部を拡張させるステップと、
c)前記ばらばらの遠位支柱端が前記管状構造の前記近位端に向かう方向を向くように、前記管状構造の内部に向かって前記ばらばらの遠位支柱端のうち少なくともいくつかを曲げるステップと、
d)前記ばらばらの遠位支柱端のうち少なくともいくつかを相互に接続するステップと、
を備える方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261671433P | 2012-07-13 | 2012-07-13 | |
US61/671,433 | 2012-07-13 | ||
PCT/US2013/050060 WO2014011865A1 (en) | 2012-07-13 | 2013-07-11 | Occlusion device for an atrial appendage |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015522360A true JP2015522360A (ja) | 2015-08-06 |
JP6133983B2 JP6133983B2 (ja) | 2017-05-24 |
Family
ID=48856996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015521803A Active JP6133983B2 (ja) | 2012-07-13 | 2013-07-11 | 心耳用閉塞装置およびその製造方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20140018841A1 (ja) |
EP (3) | EP2872051B1 (ja) |
JP (1) | JP6133983B2 (ja) |
CN (2) | CN104768476B (ja) |
CA (1) | CA2878167C (ja) |
ES (1) | ES2626878T3 (ja) |
IN (1) | IN2014DN10863A (ja) |
WO (1) | WO2014011865A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020509922A (ja) * | 2017-03-24 | 2020-04-02 | シークエント メディカル インコーポレイテッド | 身体構造の塞栓形成のためのシステムおよび方法 |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008151204A1 (en) | 2007-06-04 | 2008-12-11 | Sequent Medical Inc. | Methods and devices for treatment of vascular defects |
US9597087B2 (en) | 2008-05-02 | 2017-03-21 | Sequent Medical, Inc. | Filamentary devices for treatment of vascular defects |
US20180049731A1 (en) * | 2010-04-29 | 2018-02-22 | Muffin Incorporated | Closing device for tissue openings |
US10568628B2 (en) | 2017-05-23 | 2020-02-25 | Muffin Incorporated | Closing device for tissue openings |
US9744033B2 (en) | 2011-04-01 | 2017-08-29 | W.L. Gore & Associates, Inc. | Elastomeric leaflet for prosthetic heart valves |
US9554806B2 (en) | 2011-09-16 | 2017-01-31 | W. L. Gore & Associates, Inc. | Occlusive devices |
US10959715B2 (en) | 2012-10-31 | 2021-03-30 | W. L. Gore & Associates, Inc. | Devices and methods related to deposited support structures |
US10675012B2 (en) | 2012-11-16 | 2020-06-09 | W. L. Gore & Associates, Inc. | Joint assembly for medical devices |
US11744594B2 (en) * | 2012-11-16 | 2023-09-05 | W.L. Gore & Associates, Inc. | Space filling devices |
US11399842B2 (en) | 2013-03-13 | 2022-08-02 | Conformal Medical, Inc. | Devices and methods for excluding the left atrial appendage |
JP6423851B2 (ja) | 2013-03-13 | 2018-11-14 | アーロン・ヴィ・カプラン | 左心耳に空置術を行うためのデバイス |
US10617425B2 (en) | 2014-03-10 | 2020-04-14 | Conformal Medical, Inc. | Devices and methods for excluding the left atrial appendage |
US11911258B2 (en) * | 2013-06-26 | 2024-02-27 | W. L. Gore & Associates, Inc. | Space filling devices |
US9955976B2 (en) | 2013-08-16 | 2018-05-01 | Sequent Medical, Inc. | Filamentary devices for treatment of vascular defects |
US9078658B2 (en) | 2013-08-16 | 2015-07-14 | Sequent Medical, Inc. | Filamentary devices for treatment of vascular defects |
US9730701B2 (en) | 2014-01-16 | 2017-08-15 | Boston Scientific Scimed, Inc. | Retrieval wire centering device |
US9629635B2 (en) | 2014-04-14 | 2017-04-25 | Sequent Medical, Inc. | Devices for therapeutic vascular procedures |
WO2016038174A2 (en) * | 2014-09-12 | 2016-03-17 | Carag Ag | Occluder |
CN105796148B (zh) | 2014-12-31 | 2018-06-05 | 先健科技(深圳)有限公司 | 左心耳封堵器 |
CA2986047C (en) | 2015-05-14 | 2020-11-10 | W. L. Gore & Associates, Inc. | Devices and methods for occlusion of an atrial appendage |
EP3310264A1 (en) * | 2015-06-19 | 2018-04-25 | Koninklijke Philips N.V. | Implantable medical device and system to heat tissue |
CN105054985B (zh) * | 2015-07-28 | 2018-05-01 | 杭州诺茂医疗科技有限公司 | 一种改进的左心耳封堵器 |
EP3359771B1 (en) | 2015-12-16 | 2021-06-02 | Halliburton Energy Services, Inc. | Electrical impedance tomography using a switchable array |
CN106923884B (zh) * | 2015-12-31 | 2018-12-21 | 先健科技(深圳)有限公司 | 左心耳封堵器 |
US11389283B2 (en) * | 2016-05-11 | 2022-07-19 | W. L. Gore & Associates, Inc. | Filter and occluder systems and associated methods and devices |
CN106994030B (zh) * | 2016-06-15 | 2020-03-10 | 先健科技(深圳)有限公司 | 左心耳封堵器 |
EP4129210A1 (en) | 2016-07-22 | 2023-02-08 | Cornell University | Left atrial appendage occluder device |
US10828152B2 (en) | 2016-08-11 | 2020-11-10 | 4C Medical Technologies, Inc. | Heart chamber prosthetic valve implant with base, spring and dome sections with single chamber anchoring for preservation, supplementation and/or replacement of native valve function |
CN106333725A (zh) * | 2016-09-27 | 2017-01-18 | 张雯 | 一种左心耳封堵器以及左心耳封堵装置 |
US11426172B2 (en) | 2016-10-27 | 2022-08-30 | Conformal Medical, Inc. | Devices and methods for excluding the left atrial appendage |
EP3531926A2 (en) | 2016-10-27 | 2019-09-04 | Conformal Medical, Inc. | Devices and methods for excluding the left atrial appendage |
WO2018089311A1 (en) | 2016-11-08 | 2018-05-17 | Cardiac Pacemakers, Inc | Implantable medical device for atrial deployment |
US10653523B2 (en) | 2017-01-19 | 2020-05-19 | 4C Medical Technologies, Inc. | Systems, methods and devices for delivery systems, methods and devices for implanting prosthetic heart valves |
US10561495B2 (en) | 2017-01-24 | 2020-02-18 | 4C Medical Technologies, Inc. | Systems, methods and devices for two-step delivery and implantation of prosthetic heart valve |
CN106691521B (zh) * | 2017-02-08 | 2023-08-04 | 宁波迪创医疗科技有限公司 | 一种封堵器 |
CN107049373B (zh) * | 2017-02-08 | 2023-09-26 | 宁波迪创医疗科技有限公司 | 封堵器 |
CN106955135A (zh) * | 2017-04-07 | 2017-07-18 | 上海申淇医疗科技有限公司 | 一种封堵器阻流膜及其制造方法 |
CN110831520B (zh) | 2017-04-27 | 2022-11-15 | 波士顿科学国际有限公司 | 具有织物保持倒钩的闭塞医疗装置 |
CN108938034A (zh) * | 2017-05-23 | 2018-12-07 | 杭州诺茂医疗科技有限公司 | 一种改进密封效果的左心耳封堵器及其制备方法 |
CN109419548A (zh) * | 2017-08-21 | 2019-03-05 | 上海普实医疗器械科技有限公司 | 左心耳封堵器及其制造方法 |
EP3459469A1 (en) | 2017-09-23 | 2019-03-27 | Universität Zürich | Medical occluder device |
US11173023B2 (en) | 2017-10-16 | 2021-11-16 | W. L. Gore & Associates, Inc. | Medical devices and anchors therefor |
WO2019084358A1 (en) * | 2017-10-27 | 2019-05-02 | Boston Scientific Scimed, Inc. | OCCLUSIVE MEDICAL DEVICE WITH DAMPING ASSEMBLY |
US11191547B2 (en) | 2018-01-26 | 2021-12-07 | Syntheon 2.0, LLC | Left atrial appendage clipping device and methods for clipping the LAA |
US11284902B2 (en) | 2018-02-01 | 2022-03-29 | Boston Scientific Scimed, Inc. | Method of making a vascular occlusion device |
WO2019161072A1 (en) | 2018-02-14 | 2019-08-22 | Boston Scientific Scimed, Inc. | Occlusive medical device |
US11241239B2 (en) | 2018-05-15 | 2022-02-08 | Boston Scientific Scimed, Inc. | Occlusive medical device with charged polymer coating |
EP3801300A1 (en) | 2018-06-08 | 2021-04-14 | Boston Scientific Scimed, Inc. | Medical device with occlusive member |
US11596533B2 (en) | 2018-08-21 | 2023-03-07 | Boston Scientific Scimed, Inc. | Projecting member with barb for cardiovascular devices |
US11857441B2 (en) | 2018-09-04 | 2024-01-02 | 4C Medical Technologies, Inc. | Stent loading device |
JP2022519720A (ja) | 2019-02-08 | 2022-03-24 | コンフォーマル・メディカル・インコーポレイテッド | 左心耳を排除するためのデバイスおよび方法 |
US11317921B2 (en) | 2019-03-15 | 2022-05-03 | Sequent Medical, Inc. | Filamentary devices for treatment of vascular defects |
EP3908208A4 (en) | 2019-03-15 | 2022-10-19 | Sequent Medical, Inc. | FILAMENTARY DEVICES WITH A FLEXIBLE JOINT FOR THE TREATMENT OF VASCULAR ABNORMALITIES |
WO2020190620A1 (en) | 2019-03-15 | 2020-09-24 | Sequent Medical, Inc. | Filamentary devices for treatment of vascular defects |
WO2020198259A1 (en) | 2019-03-25 | 2020-10-01 | Laminar, Inc. | Devices and systems for treating the left atrial appendage |
CN110522486B (zh) * | 2019-04-22 | 2021-04-09 | 上海佐心医疗科技有限公司 | 用于左心耳的封堵支架 |
US10925615B2 (en) | 2019-05-03 | 2021-02-23 | Syntheon 2.0, LLC | Recapturable left atrial appendage clipping device and methods for recapturing a left atrial appendage clip |
CN114126540A (zh) | 2019-07-17 | 2022-03-01 | 波士顿科学医学有限公司 | 连续覆盖的左心耳植入物 |
US11540838B2 (en) | 2019-08-30 | 2023-01-03 | Boston Scientific Scimed, Inc. | Left atrial appendage implant with sealing disk |
CN114641242A (zh) | 2019-09-26 | 2022-06-17 | 苏黎世大学 | 左心耳闭塞装置 |
CA3161288A1 (en) * | 2019-12-27 | 2021-07-01 | Lifetech Scientific (Shenzhen) Co., Ltd. | Left atrial appendage occluder and occluding system |
US11931253B2 (en) | 2020-01-31 | 2024-03-19 | 4C Medical Technologies, Inc. | Prosthetic heart valve delivery system: ball-slide attachment |
US11992403B2 (en) | 2020-03-06 | 2024-05-28 | 4C Medical Technologies, Inc. | Devices, systems and methods for improving recapture of prosthetic heart valve device with stent frame having valve support with inwardly stent cells |
US11903589B2 (en) | 2020-03-24 | 2024-02-20 | Boston Scientific Scimed, Inc. | Medical system for treating a left atrial appendage |
US20220338877A1 (en) * | 2021-04-27 | 2022-10-27 | Boston Scientific Scimed, Inc. | Left atrial appendage implant |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6443972B1 (en) * | 1997-11-19 | 2002-09-03 | Cordis Europa N.V. | Vascular filter |
JP2003529384A (ja) * | 1998-11-06 | 2003-10-07 | イーヴィースリー サニーヴェイル インコーポレイテッド | 左心房附属物を閉塞する方法および器具 |
JP2005515830A (ja) * | 2002-01-25 | 2005-06-02 | アトリテック, インコーポレイテッド | 心耳血液ろ過システム |
US20090099647A1 (en) * | 2007-10-12 | 2009-04-16 | Aga Medical Corporation | Multi-component vascular device |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5509899A (en) | 1994-09-22 | 1996-04-23 | Boston Scientific Corp. | Medical device with lubricious coating |
US7044134B2 (en) * | 1999-11-08 | 2006-05-16 | Ev3 Sunnyvale, Inc | Method of implanting a device in the left atrial appendage |
US6673053B2 (en) | 1999-05-07 | 2004-01-06 | Scimed Life Systems, Inc. | Hydrophilic lubricity coating for medical devices comprising an antiblock agent |
US6730119B1 (en) * | 2000-10-06 | 2004-05-04 | Board Of Regents Of The University Of Texas System | Percutaneous implantation of partially covered stents in aneurysmally dilated arterial segments with subsequent embolization and obliteration of the aneurysm cavity |
US20030032976A1 (en) * | 2001-05-21 | 2003-02-13 | Boucek Mark M. | Catheter deployed partial occlusion devices and methods |
US20040111147A1 (en) * | 2002-12-03 | 2004-06-10 | Rabkin Dmitry J. | Temporary, repositionable or retrievable intraluminal devices |
US7001369B2 (en) | 2003-03-27 | 2006-02-21 | Scimed Life Systems, Inc. | Medical device |
US7597704B2 (en) * | 2003-04-28 | 2009-10-06 | Atritech, Inc. | Left atrial appendage occlusion device with active expansion |
US7288084B2 (en) | 2003-04-28 | 2007-10-30 | Boston Scientific Scimed, Inc. | Drug-loaded medical device |
US7544381B2 (en) | 2003-09-09 | 2009-06-09 | Boston Scientific Scimed, Inc. | Lubricious coatings for medical device |
EP2856949B2 (en) * | 2004-04-08 | 2019-09-11 | Aga Medical Corporation | Flanged occlusion devices |
US7914809B2 (en) | 2005-08-26 | 2011-03-29 | Boston Scientific Scimed, Inc. | Lubricious composites for medical devices |
CA2627408A1 (en) * | 2005-11-11 | 2007-05-18 | Occlutech Gmbh | Occlusion instrument for closing a cardiac auricle and a method for producing such an occlusion instrument |
US8870913B2 (en) * | 2006-03-31 | 2014-10-28 | W.L. Gore & Associates, Inc. | Catch system with locking cap for patent foramen ovale (PFO) occluder |
JP2010503482A (ja) | 2006-09-18 | 2010-02-04 | ボストン サイエンティフィック リミテッド | 内部人工器官 |
WO2008036554A2 (en) | 2006-09-18 | 2008-03-27 | Boston Scientific Limited | Endoprostheses |
ES2353827T3 (es) * | 2006-11-20 | 2011-03-07 | Septrx, Inc. | Dispositivo para la prevención del paso no deseado de émbolos desde un depósito sanguíneo venoso a un depósito sanguíneo arterial. |
EP2263605A1 (en) * | 2006-11-20 | 2010-12-22 | SeptRx, Inc. | Device and method for preventing the undesired passage of emboli from a venous blood pool to an arterial blood pool |
WO2008151204A1 (en) * | 2007-06-04 | 2008-12-11 | Sequent Medical Inc. | Methods and devices for treatment of vascular defects |
US20090028785A1 (en) | 2007-07-23 | 2009-01-29 | Boston Scientific Scimed, Inc. | Medical devices with coatings for delivery of a therapeutic agent |
EP2200674A2 (en) | 2007-09-10 | 2010-06-30 | Boston Scientific Scimed, Inc. | Medical devices with triggerable bioadhesive material |
US10123803B2 (en) * | 2007-10-17 | 2018-11-13 | Covidien Lp | Methods of managing neurovascular obstructions |
US8187222B2 (en) | 2008-09-12 | 2012-05-29 | Boston Scientific Scimed, Inc. | Devices and systems for delivery of therapeutic agents to body lumens |
US20100087783A1 (en) | 2008-10-07 | 2010-04-08 | Boston Scientific Scimed, Inc. | Medical devices for delivery of therapeutic agents to body lumens |
US20110054515A1 (en) * | 2009-08-25 | 2011-03-03 | John Bridgeman | Device and method for occluding the left atrial appendage |
CN102639181A (zh) * | 2009-11-05 | 2012-08-15 | 斯昆特医疗公司 | 多层长丝装置或血管缺损的治疗 |
CN201814682U (zh) * | 2010-09-16 | 2011-05-04 | 先健科技(深圳)有限公司 | 封堵器 |
US20120095396A1 (en) | 2010-10-18 | 2012-04-19 | Boston Scientific Scimed, Inc. | Drug Eluting Medical Device Utilizing Bioadhesives |
CN202143640U (zh) * | 2011-06-01 | 2012-02-15 | 先健科技(深圳)有限公司 | 左心耳封堵器 |
WO2013071115A1 (en) * | 2011-11-09 | 2013-05-16 | Boston Scientific Scimed, Inc. | Occlusion device |
-
2013
- 2013-07-11 CA CA2878167A patent/CA2878167C/en not_active Expired - Fee Related
- 2013-07-11 WO PCT/US2013/050060 patent/WO2014011865A1/en active Application Filing
- 2013-07-11 JP JP2015521803A patent/JP6133983B2/ja active Active
- 2013-07-11 IN IN10863DEN2014 patent/IN2014DN10863A/en unknown
- 2013-07-11 EP EP13740155.0A patent/EP2872051B1/en active Active
- 2013-07-11 CN CN201380037222.4A patent/CN104768476B/zh active Active
- 2013-07-11 EP EP17162401.8A patent/EP3213695B1/en active Active
- 2013-07-11 US US13/939,383 patent/US20140018841A1/en not_active Abandoned
- 2013-07-11 EP EP21171829.1A patent/EP3900648A1/en active Pending
- 2013-07-11 CN CN201910423025.5A patent/CN110115608B/zh active Active
- 2013-07-11 ES ES13740155.0T patent/ES2626878T3/es active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6443972B1 (en) * | 1997-11-19 | 2002-09-03 | Cordis Europa N.V. | Vascular filter |
JP2003529384A (ja) * | 1998-11-06 | 2003-10-07 | イーヴィースリー サニーヴェイル インコーポレイテッド | 左心房附属物を閉塞する方法および器具 |
JP2005515830A (ja) * | 2002-01-25 | 2005-06-02 | アトリテック, インコーポレイテッド | 心耳血液ろ過システム |
US20090099647A1 (en) * | 2007-10-12 | 2009-04-16 | Aga Medical Corporation | Multi-component vascular device |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020509922A (ja) * | 2017-03-24 | 2020-04-02 | シークエント メディカル インコーポレイテッド | 身体構造の塞栓形成のためのシステムおよび方法 |
Also Published As
Publication number | Publication date |
---|---|
IN2014DN10863A (ja) | 2015-09-11 |
CA2878167A1 (en) | 2014-01-16 |
CN110115608A (zh) | 2019-08-13 |
CA2878167C (en) | 2018-03-13 |
EP2872051A1 (en) | 2015-05-20 |
CN110115608B (zh) | 2023-03-24 |
EP3213695A3 (en) | 2017-11-08 |
CN104768476A (zh) | 2015-07-08 |
EP2872051B1 (en) | 2017-03-29 |
US20140018841A1 (en) | 2014-01-16 |
EP3213695B1 (en) | 2021-05-05 |
WO2014011865A8 (en) | 2014-03-06 |
EP3900648A1 (en) | 2021-10-27 |
EP3213695A2 (en) | 2017-09-06 |
CN104768476B (zh) | 2019-05-31 |
WO2014011865A1 (en) | 2014-01-16 |
ES2626878T3 (es) | 2017-07-26 |
JP6133983B2 (ja) | 2017-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6133983B2 (ja) | 心耳用閉塞装置およびその製造方法 | |
US11903850B2 (en) | Anti-thrombogenic medical devices and methods | |
CN101102728B (zh) | 具有可自展开部分的支架 | |
US9861370B2 (en) | Occlusion device | |
JP5615893B2 (ja) | ステントと繊維の構造的組み合わせ | |
JP5432909B2 (ja) | 生体内留置用ステントおよびステントデリバリーシステム | |
JP2010532683A (ja) | 生体吸収性膜を備えたステント | |
JP2014531275A (ja) | 末梢用途のための改良されたスキャフォールド | |
EP2967935A1 (en) | Coated medical devices and methods of making and using same | |
CA2756092A1 (en) | Method of manufacturing a polymeric stent having improved toughness | |
WO2009121048A1 (en) | Method of manufacturing a polymeric stent having a circumferential ring configuration | |
JP4526589B2 (ja) | カバードステント | |
JP2005074154A (ja) | 生体留置用補綴物組立体およびその製造方法 | |
JP2005152004A (ja) | カバードステント | |
JP2005118123A (ja) | ステントおよびその製造方法 | |
JP2018500131A (ja) | 抑制端を有する拡張可能なステント |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150121 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150121 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20151211 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151222 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160316 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160622 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161122 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170307 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170404 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170420 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6133983 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |